Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
Table 2
ICIQ-SF questionnaire. Changes from baseline after 12 months of treatment with OXY-TDS.
ICIQ-SF questionnaire
Pretreatment patients
Posttreatment patients
value
No urine leaks
2 (4.3%)
18 (38.3%)
<0.001
Leaks before you can get to the toilet
41 (87.2%)
22 (46.81%)
<0.001
Leaks when you cough or sneeze
18 (38.30%)
7 (14.9%)
0.013
Leaks when you are asleep
11 (23.4%)
3 (6.4%)
0.008
Leaks when you are physically active/exercising
16 (34.04%)
7 (14.9%)
0.035
Leaks when you have finished urinating
9 (19.15%)
2 (4.3%)
0.039
Leaks for no obvious reason
15 (31.91%)
2 (4.3%)
<0.001
Leaks all the time
2 (4.25%)
0 (0.0%)
NA
ICIQ-SF item 1 and 2 = 0
2
19
<0.001
ICIQ-SF item 1 or 2 > 0
45
27
ICIQ-SF = 0
2
12
0.002
ICIQ-SF > 0
45
34
M (SD)
M (SD)
Change (95% CI)
Total score
13.40 (4.5)
5.13 (4.5)
−8 (−10.0; −6.5) value 0.000
Statistical tests: Student’s t-test (variables with normal distribution) or Wilcoxon signed rank test (variables with nonnormal distribution); McNemar.
